NextCure (NXTC) Total Liabilities (2018 - 2026)
NextCure (NXTC) posted quarterly Total Liabilities of $11.3 million for Q1 2026, little changed year-over-year from $11.3 million in Q1 2025, and down 26.11% quarter-over-quarter from $15.2 million in Q4 2025.
NextCure (NXTC) Total Liabilities (2018 - 2026) Analysis & Trends
NextCure's Total Liabilities history runs 9 years deep, the most recent figure standing at $11.3 million for Q1 2026.
- In Q1 2026, Total Liabilities changed 0.19% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $11.3 million (changed 0.19% YoY), while the FY2025 annual figure was $15.2 million, down 0.96% from the prior year.
- Total Liabilities for Q1 2026 stood at $11.3 million, down from $15.2 million in the prior quarter.
- The five-year high for Total Liabilities was $17.1 million in Q2 2024, with the low at $8.2 million in Q2 2022.
- The 5-year median for Total Liabilities is $14.8 million (2024), against an average of $13.6 million.
- Peak annual rise in Total Liabilities reached 84.79% in 2022, while the deepest fall reached 30.5% in 2022.
- NextCure's Total Liabilities stood at $16.6 million in 2022, then declined by 18.12% to $13.6 million in 2023, then climbed by 13.01% to $15.4 million in 2024, then decreased by 0.96% to $15.2 million in 2025, then decreased by 26.11% to $11.3 million in 2026.
- Business Quant data shows NXTC's Total Liabilities at $11.3 million in Q1 2026, $15.2 million in Q4 2025, and $16.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 10.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.47 Mn |
| Mar 31, 2026 | 11.26 Mn |
| Dec 31, 2025 | 15.24 Mn |
| Sep 30, 2025 | 15.97 Mn |
| Jun 30, 2025 | 16.04 Mn |
| Mar 31, 2025 | 11.28 Mn |
| Dec 31, 2024 | 15.39 Mn |
| Sep 30, 2024 | 14.75 Mn |
| Jun 30, 2024 | 17.15 Mn |
| Mar 31, 2024 | 16.11 Mn |
| Dec 31, 2023 | 13.62 Mn |
| Sep 30, 2023 | 13.49 Mn |
| Jun 30, 2023 | 14.95 Mn |
| Mar 31, 2023 | 13.59 Mn |
| Dec 31, 2022 | 16.63 Mn |
| Sep 30, 2022 | 8.37 Mn |
| Jun 30, 2022 | 8.17 Mn |
| Mar 31, 2022 | 8.81 Mn |
| Dec 31, 2021 | 9.00 Mn |
| Sep 30, 2021 | 9.60 Mn |